Actuate Therapeutics: Cash Runway to September 2026, Nasdaq Delisting Risk
ACTU is trading near its 52-week low of $0.9 (10% above the low).
Summary
Actuate Therapeutics' Q2 2026 report shows a cash runway only to September 2026, ongoing Nasdaq delisting risk, and modest ATM sales, despite recent clinical progress.
Key Events · Earnings and Guidance · ACTU
-
Cash Runway to September 2026
Cash and cash equivalents of $4.4 million as of June 30, 2026, with management estimating funds will last only until September 2026 without additional capital.
-
ATM Facility Sales
Sold 498,193 shares at a weighted-average price of $2.66 per share for net proceeds of $1,249,591 during H1 2026; $98.7 million remaining capacity.
-
Nasdaq Delisting Notice
Received notice on July 15, 2026 for MVLS below $50 million; compliance deadline January 11, 2027.
-
FDA Clearance for Oral Tablet
Received FDA clearance to proceed with Phase 1/2 clinical study of Elraglusib Oral Tablet in advanced refractory cancers.
Analysis · ACTU · Life Sciences
A net loss of $10.5 million for the first half of 2026 leaves Actuate Therapeutics with $4.4 million in cash and equivalents as of June 30, 2026. Management now projects that these funds will sustain operations only until September 2026—a slight extension from the prior July 2026 estimate, yet still a critical liquidity crunch. The company raised $1.25 million in net proceeds by selling 498,193 shares under its ATM facility at a weighted-average price of $2.66 per share, but this is insufficient to address the going concern warning. Additionally, Nasdaq has initiated delisting proceedings after the market value fell below the $50 million minimum, with a compliance deadline of January 11, 2027. On the positive side, FDA clearance was received to proceed with a Phase 1/2 study of the oral tablet formulation of elraglusib, and an agreement was entered for a pediatric neuroblastoma trial, but these developments are overshadowed by the immediate financing needs.
At the time of this filing, ACTU was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.2M. The 52-week trading range was $0.90 to $9.22. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.